Neurodegeneration: Linking Cellular Pathways to Therapeutic Strategies

Neurodegeneration: Linking Cellular Pathways to Therapeutic Strategies is organized by Keystone Symposia on Molecular and Cellular Biology and will be held from Jun 08 - Oct 11, 2024 at Whistler Conference Centre, Whistler, British Columbia, Canada.

Description:
Neurodegenerative diseases are common but largely untreatable, despite massive investments from both academic and industry sectors. Tackling these diseases will require a collective and integrated effort to address the challenges of identifying, understanding, and translating cellular mechanisms of neurodegeneration into effective therapies.

This meeting will take an innovative approach by assembling speakers and attendees across diverse fields, creating synergy between geneticists, cell biologists, computational biologists, clinicians, and patients to broaden, deepen and integrate our understanding of these diseases. These experts will illustrate how genomics, technology, computational advances, and a focus on convergent cellular pathways will drive innovation and discovery in the field, irrespective of entrenched models. The program will feature new voices in the field, who will generate discussion around new and innovative ideas and directions.

Specifically, the program will:

• Leverage human genetics and genomics to identify convergent and divergent disease pathways;
• Explore new findings in key cellular pathways of neurodegeneration and aging;
• Highlight transformative technologies that enable cell biology at scale in the context of neurodegenerative disease;
• Demonstrate how discoveries are translated into new therapies with an eye towards enhancing inclusion in clinical research and trials;
• Engage with key stakeholders regarding the digital era of neuroscience.

We anticipate that attendees will leave this meeting with a deeper appreciation of how genetic discoveries inform and inspire mechanistic inquiries about cellular disease mechanisms, and how new discoveries and new technologies are driving a revolution in how neurodegenerative diseases are classified and treated.